Aono T, Kaneko M, Numata Y, Takahashi Y, Yamamoto T, Kumashiro H
Folia Psychiatr Neurol Jpn. 1981;35(2):115-21.
During a four-week open study, amoxapine (AX), a new antidepressant agent, was administered to seven patients with pseudoneurotic schizophrenia, seven with neurosis and another seven with schizophrenia, all having similar symptoms. The improvement ratio was 71.4% in the pseudoneurotic schizophrenia group, 57.1% in the neurosis group and 42.8% in the schizophrenia group. Through the application of rating instruments, improvements were observed in the pseudoneurotic schizophrenia group in such items as psychotic and psychoneurotic symptoms in the assessment through the Springfield Outpatient Symptom and Adjustment Index, somatic concern and blunted affect through the Brief Psychiatric Rating Scale, and depression and depersonalization through the Clinical Rating Scale. On the other hand, overall improvements were less seen in the items of the neurosis group and the schizophrenia group. Effective doses of AX were 30 to 75 mg/day in the three groups. Side effects were observed in four cases which included insomnia, tachycardia, palpitation and hypomanic state. There were no cases in which AX was discontinued because of the side effects as these symptoms were slight. AX is remarkable and characteristically efficacious in the pseudoneurotic schizophrenia, and this effectiveness is presumed due to its antidepressant and antipsychotic actions.
在一项为期四周的开放性研究中，新型抗抑郁药阿莫沙平（AX）被给予7例假性神经症型精神分裂症患者、7例神经症患者和另外7例精神分裂症患者，所有患者症状相似。假性神经症型精神分裂症组的改善率为71.4%，神经症组为57.1%，精神分裂症组为42.8%。通过使用评定工具，在假性神经症型精神分裂症组中观察到，通过斯普林菲尔德门诊症状与适应指数评估的精神病性和精神神经症症状、通过简明精神病评定量表评估的躯体关注和情感迟钝、以及通过临床评定量表评估的抑郁和人格解体等项目都有改善。另一方面，神经症组和精神分裂症组的项目总体改善较少。三组中AX的有效剂量为30至75毫克/天。有4例出现副作用，包括失眠、心动过速、心悸和轻躁狂状态。由于这些症状轻微，没有因副作用而停用AX的病例。AX在假性神经症型精神分裂症中具有显著且独特的疗效，这种有效性推测是由于其抗抑郁和抗精神病作用。
